Cargando…
PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
Current therapy for BCL-2-associated tumors such as Non-Hodgkin Lymphomas (NHL) is inadequate. The DNAi PNT2258, a 24 base single-stranded phosphodiester DNA oligodeoxynucleotide (PNT100) encapsulated in a protective liposome, was precisely designed to treat cancers that over-express BCL-2. PNT2258...
Autores principales: | Ebrahim, Abdul Shukkur, Kandouz, Mustapha, Liddane, Allison, Sabbagh, Hussam, Hou, Yuning, Li, Chunying, Al-Katib, Ayad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173141/ https://www.ncbi.nlm.nih.gov/pubmed/27283896 http://dx.doi.org/10.18632/oncotarget.9872 |
Ejemplares similares
-
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
por: Tolcher, Anthony W., et al.
Publicado: (2013) -
Spatio-temporal regulation of EGFR signaling by the Eps15 homology domain-containing protein 3 (EHD3)
por: Amessou, Mohamed, et al.
Publicado: (2016) -
Unintended target effect of anti-BCL-2 DNAi
por: Ebrahim, Abdul Shukkur, et al.
Publicado: (2017) -
Isolation and characterization of a CD34(+) sub-clone in B-cell lymphoma
por: Al-Katib, Ayad M., et al.
Publicado: (2020) -
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
por: Raufi, Ali, et al.
Publicado: (2013)